Lucid Diagnostics Reports $1.5 Million Revenue for Second Quarter

The company reported an operating loss of approximately $14.3 million for the quarter ending June 30, 2026, with a net loss attributable to common stockholders of $14.7 million. Despite these figures, CEO Lishan Aklog highlighted significant operational progress, specifically the company's first laboratory benefit manager coverage policy for EsoGuard. This agreement, secured through Concert, establishes the test as a medically necessary procedure for patients meeting specific screening criteria.

Lucid maintains a cash position of $33.4 million, a slight decrease from the $34.7 million held at the end of 2025. Management continues to prioritize health economic modeling to demonstrate the long-term cost-effectiveness of its testing, aiming to accelerate adoption among health systems and the VA. The company is currently awaiting a draft Medicare coverage policy, which remains a critical milestone for its broader clinical strategy.